Search

Search Results

• 

  Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients

  S. Soldano, P. Montagna, R. Brizzolara, C. Ferrone, A. Parodio, A. Sulli, B. Seriolo, B. Villaggio, M. Cutolo

  326-334

  11-12-2012

  https://doi.org/10.4081/reumatismo.2012.326

  1919

  PDF: 989
• 

  Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids

  S. Parisi, M. Bruzzone, C. Centanaro Di Vittorio, A. Laganà, C.L. Peroni, E. Fusaro

  286-291

  17-03-2014

  https://doi.org/10.4081/reumatismo.2013.691

  2949

  PDF: 1333

• Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)

  M.T. Riccardi, A. Chialà, F. Iannone, V. Grattagliano, M. Covelli, G. Lapadula

  135-139

  https://doi.org/10.4081/reumatismo.2007.135

  1343

  PDF: 835

• Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases

  H. Marotta, R. Montisci, F. Tiso, S. Pontarollo, M. Rizzo, F. Tona, S. Iliceto, F. Cozzi

  299-303

  https://doi.org/10.4081/reumatismo.2007.299

  1060

  PDF: 817

• Digital ulcers in a cohort of 333 scleroderma patients

  F. Tiso, M. Favaro, L. Ciprian, S. Cardarelli, M. Rizzo, M. Tonello, A. Ruffatti, F. Cozzi

  215-220

  https://doi.org/10.4081/reumatismo.2007.215

  1258

  PDF: 949